english.prescrire.org > Spotlight > 100 most recent > RSVpreF vaccine (Abrysvo°) during pregnancy to prevent RSV infection in the woman's child after birth

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

RSVpreF vaccine (Abrysvo°) during pregnancy to prevent RSV infection in the woman's child after birth

 Marketing Authorisations   RSVpreF vaccine was authorised in the European Union in mid-2023 for pregnant women between weeks 24 and 36 of gestation, to prevent respiratory syncytial virus (RSV) infection in their children from birth to 6 months of age. Does maternal vaccination during pregnancy provide more effective protection for infants, or provoke fewer or milder adverse effects, than the administration of nirsevimab or palivizumab to the infant? 
Full article available for download by subscribers (4 pages)

©Prescrire 1 April 2024

Source: "VRSVpreF vaccine (Abrysvo°) during pregnancy to prevent RSV infection in the woman's child after birth" Prescrire Int 2024; 33 (258): 89-92. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter

Subscribe now

See also:

"Nirsevimab (Beyfortus°)
to prevent RSV infection
in infants. For infants at risk
of developing severe
disease: more convenient
than palivizumab"
Prescrire Int 2023;
32 (254): 285-287.
Subscribers only

"Palivizumab:
moderate reduction
in hospitalisation rate"
Prescrire Int 2004;